

Supplementary Online Content

Bruner DW, Pugh SL, Lee WR, et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. *JAMA Oncol*. Published online February 14, 2019. doi:10.1001/jamaoncol.2018.6752

eTable. Significant patient and tumor characteristics by EPIC completion status at 6, 12, 24, and 60 months

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Significant Patient and Tumor Characteristics by EPIC Completion Status at 6, 12, 24, and 60 Months

	Missing Assessment	Complete Assessment	P-value
6 Months	(n=261)	(n=701)	
RT Modality (received)			
3D-CRT	67 (26.5%)	115 (16.5%)	0.0007
IMRT	186 (73.5%)	584 (83.5%)	
Planned RT Modality (at registration)			
3D-CRT	73 (28.0%)	123 (17.5%)	0.0006
IMRT	188 (72.0%)	578 (82.5%)	
12 months	(n=327)	(n=635)	
Age (years)			
≤65	166 (50.8%)	250 (39.4%)	0.0008
>65	161 (49.2%)	385 (60.6%)	
Planned RT Modality (at registration)			
3D-CRT	81 (24.8%)	115 (18.1%)	0.018

eTable 1. Significant Patient and Tumor Characteristics by EPIC Completion Status at 6, 12, 24, and 60 Months

	Missing Assessment	Complete Assessment	P-value
IMRT	246 (75.2%)	520 (81.9%)	
<hr/>			
60 months	(n=428)	(n=534)	
Race			
Other	103 (24.1%)	86 (16.3%)	0.0032
White	324 (75.9%)	441 (83.7%)	
Ethnicity			
Hispanic or Latino	22 (5.4%)	7 (1.4%)	0.0010
Not Hispanic or Latino	384 (94.6%)	476 (98.6%)	
Planned RT Modality (at registration)			
3D-CRT	73 (17.1%)	123 (23.0%)	0.024
IMRT	355 (82.9%)	411 (77.0%)	
<hr/>			
P-value from two-sided Fisher's exact test			